Is there a double standard when it comes to dementia care?

International Journal of Clinical Practice, Supplement

Volumn 59, Issue 146, 2005, Pages 3-7

  Wilkinson, David ^a  

^a MOORGREEN HOSPITAL   (United Kingdom)

Author keywords

Alzheimer's disease; Cost; Dementia; Drug treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PLACEBO; RIVASTIGMINE; WARFARIN; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; CANCER; CLINICAL OBSERVATION; DEMENTIA; EARLY DIAGNOSIS; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH ECONOMICS; HEART DISEASE; HUMAN; INTERNATIONAL COOPERATION; MULTIINFARCT DEMENTIA; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STROKE; ECONOMICS; EUROPE; HEALTH CARE QUALITY;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; EUROPE; HUMANS; MEMANTINE; NEUROPROTECTIVE AGENTS; QUALITY OF HEALTH CARE;

EID: 14744289874     PISSN: 1368504X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-504x.2005.00479.x     Document Type: Review

References (34)

1. Lobo A, Launer LJ, Fratiglioni L et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54 (Suppl. 5): S4-9.
2. Iliffe S, Manthorpe J, Eden A. Sooner or later? Issues in the early diagnosis of dementia in general practice: a qualitative study. Fam Pract 2003; 20: 376-81.
3. European Stroke Initiative. Retrieved from http://www.euri-stroke.com
4. Wild S, Roglic G, Green A et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-53.
5. Ferlay J et al. GLOBOCAN 2000 Cancer Incidence, Mortality and Prevalence Worldwide. Lyon, France: IARCP Press, 2001.
6. Boise L, Camicioli R, Morgan DL et al. Diagnosing dementia: perspectives of primary care physicians. Gerontologist 1999; 39: 457-64.
7. European Brain Council. The brain in health and disease. Retrieved from http://braindamagerepair.hiim.hr/Links/ebcpaper.html
8. Lowin A, Knapp M, McCrone P. Alzheimer's disease in the UK: comparative evidence on cost of illness and volume of health services research funding. Int J Geriatr Psychiatry 2001; 16: 1143-8.
9. United Nations. Population Division, Department of Economic and Social Affairs, United Nations Secretariat. The ageing of the world's population. Retrieved from http://www.un.org/esa/socdev/ageing/agewpop.htm; accessed 16 November 2004.
10. World Health Report 2001. Mental health: new understanding, new hope. Geneva, Switzerland: World Health Organization, 2001.
11. Andersen-Ranberg K, Vasegaard L, Jeune B. Dementia is not inevitable: a population-based study of Danish centenarians. J Gerontol B Psychol Sci Soc Sci 2001; 56: P152-9.
12. Feldman H, Gauthier S, Hecker J et al. for the Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737-44.
13. Krishnan KRR, Charles HC, Doraiswamy PM et al. Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. Am J Psychiatry 2003; 160: 2003-11.
14. Lanctôt KL, Herrmann N, Yau KK et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003; 169: 557-64.
15. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-31.
16. Rogers SL, Farlow MR, Doody RS et al. A 24-week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology 1998; 50: 136-45.
17. Burns A, Rossor M, Hecker J et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999; 10: 237-44.
18. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.
19. Windblad B, Engedal K, Soininen H et al. A 1-year randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-95.
20. Rösler M, Anand R, Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomized controlled trial. BMJ 1999; 318: 633-40.
21. Farlow M, Anand R, Missina J Jr et al. A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease. Eur Neurol 2000; 44: 236-41.
22. Raskind MA, Peskind ER, Wessel T, Yuan W. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-8.
23. Tariot PN, Solomon PR, Morris JC et al. A 5-month, randomized placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269-76.
24. Feldman H, Gauthier S, Hecker J et al. for the Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-20.
25. Doraiswamy PM, Krishnan KR, Anand R et al. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: dose early initiation of therapy offer sustained benefits? Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 705-12.
26. Wilkinson DG, Hock C, Farlow M et al. Galantamine provides broad benefits in patients with 'advanced moderate' Alzheimer's disease (MMSA ≤12) for up to six months. Int J Clin Pract 2002; 56: 509-14.
27. Reisberg B, Doody D, Stöffler A et al. for the Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
28. Tariot PN, Farlow MR, Grossberg GT et al. for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized, controlled trial. JAMA 2004; 291: 317-24.
29. Geldmacher DS. Long-term cholinesterase inhibitor therapy for Alzheimer's disease: practical considerations for the primary care physician. Prim Care Companion J Clin Psychiatry 2003; 5: 251-9.
30. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
31. National Institute for Clinical Excellence. Drugs for Alzheimer's disease - Full Guidance, No. 19, 2001. Retrieved from http://www.nice.org.uk; accessed 16 November 2004.
32. Alzheimer's Society. London, UK, 2004 (8 June, press release).
33. Datamonitor Treatment Algorithms Survey, 2002.
34. Wilkinson D, Stave C, Keohane D, Vincenzino O. The role of general practitioners in the diagnosis and treatment of Alzheimer's disease: a multinational survey. J Int Med Res 2004; 32: 149-59.